BioXcel Therapeutics, Inc. (BTAI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.07 |
| Open | 0.09 |
| Day High | 0.09 |
| Day Low | 0.07 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.02 |
| Volume | 47.48M |
| Average Volume | 6.41M |
| Market Cap | 2.28M |
| PE | -0.01 |
| EPS | -5.75 |
| Moving Average 50 Days | 0.71 |
| Moving Average 200 Days | 1.27 |
| Change | 0 |
Data not available
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
GlobeNewswire Inc.
Mar 11, 2026 8:20 PM GMT
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the clo
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
GlobeNewswire Inc.
Mar 10, 2026 6:36 PM GMT
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that i
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
GlobeNewswire Inc.
Mar 05, 2026 12:00 PM GMT
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal Opioid use disorder is a gl